206 related articles for article (PubMed ID: 35094709)
1. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
2. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.
Hori Y; Hirose K; Aramaki-Hattori N; Suzuki S; Nakayama R; Inoue M; Matsui T; Kohara M; Toyosawa S; Morii E
Diagn Pathol; 2020 Jul; 15(1):98. PubMed ID: 32711543
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
Guan R; Kang Z; Li L; Yan X; Gao T
PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
[TBL] [Abstract][Full Text] [Related]
6. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
9. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
10. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
12. Fibroadipose vascular anomaly: a clinicopathological study of 75 cases.
Xue S; Liu Q; Zhao Y; Kong L; Fu F; Gong Y; Guo X; Dong C; Wang M
Histopathology; 2023 Aug; 83(2):286-297. PubMed ID: 37099413
[TBL] [Abstract][Full Text] [Related]
13. Somatic activating mutations in
Rodriguez-Laguna L; Agra N; Ibañez K; Oliva-Molina G; Gordo G; Khurana N; Hominick D; Beato M; Colmenero I; Herranz G; Torres Canizalez JM; Rodríguez Pena R; Vallespín E; Martín-Arenas R; Del Pozo Á; Villaverde C; Bustamante A; Ayuso C; Lapunzina P; Lopez-Gutierrez JC; Dellinger MT; Martinez-Glez V
J Exp Med; 2019 Feb; 216(2):407-418. PubMed ID: 30591517
[TBL] [Abstract][Full Text] [Related]
14. Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic
Driskill JH; Hwang H; Callan AK; Oliver D
Case Rep Genet; 2022; 2022():9016497. PubMed ID: 35967928
[TBL] [Abstract][Full Text] [Related]
15. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
16. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
[TBL] [Abstract][Full Text] [Related]
19. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
[TBL] [Abstract][Full Text] [Related]
20. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
